Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. · 2018

Read Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. by Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5852359.txt.

Introduction

Vanderwalde and co-authors read microsatellite instability straight from sequencing panels. Their study appeared in Cancer Medicine. The marker flags tumors likely to answer immune checkpoint drugs. Their assay needs no matched normal tissue sample.

Across 2,189 cases, the sequencing call matched PCR testing closely. Mismatch repair status from tissue staining agreed as well. The team then scanned 11,348 patients spanning 26 cancer types. High instability turned up in 23 of those types. It overlapped only loosely with mutational burden and PD-L1. Few tumors carried all three markers at once. The authors argue each test adds its own signal.

Catalog record

CREATORVanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5852359

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients By Ari Vanderwalde, David Spetzler, Nianqing Xiao, Zoran Gatalica, John Marshall Published in: Cancer Medicine DOI: 10.1002/cam4.1372 ABSTRACT Abstract Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next‐generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer types and does not require matched samples from normal tissue. Here, we describe the MSI‐NGS method and explore the relationship of MSI with tumor mutational burden (TMB) and PD‐L1. MSI examined by PCR fragment analysis and NGS was compared for 2189 matched cases. Mismatch repair status by immunohistochemistry was compared to MSI‐NGS for 1986 matched cases. TMB was examined by NGS, and PD‐L1 was determined by immunohistochemistry. Among 2189 matched cases that spanned 26 cancer types, MSI‐NGS, as compared to MSI by PCR fragment analysis, had sensitivity of 95.8% (95% confidence interval [CI] 92.24, 98.08), specificity of 99.4% (95% CI 98.94, 99.69), positive predictive value of 94.5% (95% CI 90.62, 97.14), and negative predictive value of 99.2% (95% CI, 98.75, 99.57). High MSI (MSI‐H) status was identified in 23 of 26 cancer types. Among 11,348 cases examined (including the 2189 matched cases), the overall rates of MSI‐H, TMB‐high, and PD‐L1 positivity were 3.0%, 7.7%, and 25.4%, respectively. Thirty percent of MSI‐H cases were TMB‐low, and only 26% of MSI‐H cases were PD‐L1 positive. The overlap between TMB, MSI, and PD‐L1 differed among cancer types. Only 0.6% of the cases were positive for all three markers. MSI‐H status can be determined by NGS across cancer types. MSI‐H offers distinct data for treatment decisions regarding immune checkpoint inhibitors, in addition to the data available from TMB and PD‐L1. INTRODUCTION Microsatellite instability (MSI) involves the gain or loss of nucleotides from microsatellite tracts, which are DNA elements composed of repeating motifs that occur as alleles of variable lengths 1. MSI can result from inherited mutations or originate somatically. Lynch syndrome results from inherited mutations of known mismatch repair (MMR) genes. Tumors are classified as MMR‐deficient (dMMR) if they have somatic or germ line mutations. MSI can also occur due to epigenetic changes or altered microRNA pathways affecting MMR proteins, or without a loss of a known underlying protein 2. MSI is most commonly found in colon and endometrial cancers (the most common Lynch syndrome cancer types); however, recent analyses have found MSI in as many as 24 cancer types, suggesting that MSI is a generalized cancer phenotype 3, 4, 5, 6. MSI has been associated with improved prognosis, but until the recent advent of immune checkpoint inhibitors, the predictive use of MSI has been limited. A proof‐of‐concept study including 87 patients with 12 different cancer types demonstrated the predictive value of MSI status to predict response of solid tumors to the anti‐PD‐1 agent pembrolizumab 5, 7. This ability of MSI to predict pembrolizumab response has led to the first tumor‐agnostic drug approval by the FDA in May 2017. Additional evidence showed an improved response for MSI‐high (MSI‐H) patients to the anti‐PD‐1 agents nivolumab and MEDI0680, the anti‐PD‐L1 agent durvalumab, and the anti‐CTLA‐4 agent ipilimumab 7, 8, 9, 10. These results elevate MSI status as a third, possibly independent, predictive biomarker for immune checkpoint inhibitors, along with PD‐L1 and tumor mutational burden (TMB) 11, 12, 13, 14, 15, 16, 17. Given that patient responses to these drugs can be highly durable 5, 7, 18, it is critical to identify as many potential responders as possible. Therefore, a method to efficiently determine MSI status for every cancer patient is needed. Currently, MSI is most commonly detected through polymerase chain reaction (PCR) by fragment analysis (FA) of five conserved satellite regions, which is considered the gold standard method for MSI detection 1, 19. FA is not ideal in the clinic, however, as it requires samples of both tumor and normal tissue. As a result, FA is not always feasible for cases with limited amounts of tissue, including the analysis of cancer metastases, which are commonly submitted as biopsies and may contain few normal cells. Additionally, determining MSI by FA and MMR analysis from immunohistochemistry (IHC) is performed as stand‐alone tests and would be inefficient to perform on every patient with cancer, given that the incidence of MSI is only about 5% across cancer types 5. As broad tumor profiling becomes a common part of care for patients with cancer, it would be preferable to determine MSI status from sequencing panel results. Next‐generation sequencing (NGS) was recently found to be feasible to determine MSI status, but the published techniques require the use of paired tumor and normal tissue 3, 6. Given a large database of samples with both broad NGS results and matching MSI/dMMR status by FA/IHC, we hypothesized that we could develop and technically validate an NGS‐based MSI assay without the need for matched samples from normal tissue. Here, we describe our process for developing such a method and explore the relationship of MSI with other immunotherapy markers, specifically TMB and PD‐L1. MATERIAL AND METHODS Patient cohort For development of the NGS assay, 2189 cases were retrospectively selected based on having data available for both the 592‐gene sequencing panel and MSI testing by PCR‐FA (assay details below). For the TMB, PD‐L1, and MSI‐NGS comparison, 11,348 patients were retrospectively selected based on available data from commercial comprehensive sequencing profiles performed on their tumors by a commercial laboratory (Caris Life Sciences, Phoenix, AZ, USA) that included PD‐L1 by immunohistochemistry (IHC) and the 592‐gene sequencing panel. This research used a collection of existing data that were deidentified prior to analysis. As this research was compliant with 45 CFR 46.101(b), the project was deemed exempt from IRB oversight and consent requirements were waived. Fragment analysis by PCR MSI‐FA was tested by the fluorescent multiplex PCR‐based method (MSI Analysis: Promega, Life Sciences, Madison, WI, USA). Next‐generation sequencing NGS was performed on genomic DNA isolated from formalin‐fixed paraffin‐embedded (FFPE) tumor samples using the NextSeq platform (Illumina Inc., San Diego, CA, USA). A custom‐designed SureSelect XT assay (Agilent Technologies, Santa Clara, CA, USA) was used to enrich the 592 whole‐gene targets that comprised a 592‐gene NGS panel. All variants were detected with >99% confidence based on allele frequency and baited capture pull‐down coverage with an average sequencing depth of over 500X and an analytic sensitivity of 5% variant frequency. Microsatellite instability by NGS Microsatellite loci in the target regions of a 592‐gene NGS panel were first identified using the MISA algorithm (pgrc.ipk‐gatersleben.de/misa/), which revealed 8921 microsatellite locations. Subsequent analyses excluded sex chromosome loci, microsatellite loci in regions that typically have lower coverage depth relative to other genomic regions, and microsatellites with repeat unit lengths greater than five nucleotides. These exclusions resulted in 7317 target microsatellite loci. Patient DNA was sequenced by NGS using the 592‐gene panel. We examined the 7317 target microsatellite loci and compared them to the reference genome hg19 from the UCSC Genome Browser database (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/). The number of microsatellite loci that were altered by somatic insertion or deletion was counted for each patient sample. Only insertions or deletions that increased or decreased the number

Read the complete text